FindTrial
Sign In

Treatment of Neuroleptic Induced Acute Akathisia With Trazodone

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00659919
Enrollment
13
Registered
2008-04-17
Start date
2000-11-30
Completion date
2003-12-31
Last updated
2008-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Brief summary

Administration of trazodone for the treatment of neuroleptic induced acute akathisia in a cross-over fashion of 6 days duration. 3 days of placebo and 3 days of trazodone.

Interventions

DRUGPlacebo
DRUGTrazodone

Sponsors

BeerYaakov Mental Health Center
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Patients with akathisia according to DSM-IV criteria at least mild akathisia.

Exclusion criteria

* Change of pharmacologic regimen 7 days prior to study entry * Significant systemic disease * The presence of chronic akathisia * Patients unable to cooperate

Design outcomes

Primary

MeasureTime frame
Barnes Akathisia rating scale, Positive and Negative syndrome scale, Hamilton Depression Rating Scale, Hamilton Anxiety Scale, Clinical Global Impression, Scale for the Assessment of Negative Symptoms—

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026